000			03887nam a2200433 c 4500
999			_c7318 _d7318
001			7318
003			ES-MaUEC
005			20201203160831.0
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
008			190717s2019 gw a o |||| 0|eng d
020			_a9783030203153
024	7		_a10.1007/978-3-030-20315-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC633 _b.T47 2019 EB
245	0	0	_aThrombosis and Hemostasis in Cancer _cedited by Gerald Soff.
250			_a1st ed. 2019.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2019.
300			_a1 recurso en línea (XIV, 203 páginas)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCancer Treatment and Research _x0927-3042 _v179
490	0		_aMedicine (Springer-11650)
505	0		_aThrombosis and Hemostasis in Cancer. Scope of the Problem and Overview -- Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients -- Pathophysiology 3. The role of platelets in cancer biology -- The risk of thrombosis in cancer. Clinical factors & possible role of primary prophylaxis -- Biomarkers of cancer-associated thromboembolism -- Thrombotic Risk from Chemotherapy and Other Cancer Therapies -- Treatment of VTE In Cancer. Historical Perspective and evolving role of the DOACs -- Etiology and Management of Upper Extremity, Central line associated thrombosis -- Management of Thrombocytopenia In Cancer Patients -- Microangiopathy in Cancer. Causes, Consequences, and Management -- Thrombosis in the Philadelphia chromosome-negative Myeloproliferative Neoplasms -- Anticoagulation in the setting of primary and metastatic brain tumors -- Hemorrhage in the cancer patient. APML and other specific high risk situations.
520	3		_aIn this book, leaders in the field explore our current understanding of thrombosis and hemostasis in cancer and address key questions on the subject. Among the topics discussed are the mechanisms that cancers use to activate the coagulation system, and those by means of which an activated coagulation system can lead to more aggressive cancer growth. Clinical chapters examine the role of thrombosis prophylaxis and treatment, central line-associated thrombosis, and cancer-associated hemorrhage. Subsequent chapters deal with the management of chemotherapy-induced thrombocytopenia, anticoagulation in the presence of brain metastases, and other unique challenges in the interaction of thrombosis and hemostasis in cancer. It has been 150 years since Armand Trousseau first described the well-known association between cancer and an increased risk of thrombosis, which may be considered the first paraneoplastic syndrome ever identified. More recently, numerous studies have indicated that activation of the coagulation system by cancer not only increases the likelihood of thrombosis, but is also associated with a more aggressive cancer phenotype. By familiarizing readers with the latest developments in this complex and challenging field, the book offers a valuable resource for scientists and clinicians alike. .
988			_aSegundosemestre_2019_Medicine
650		7	_2embne _9169169 _aSangre _xEnfermedades
700	1		_aSoff, Gerald _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106937
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783030203146
776	0	8	_iPrinted edition: _z9783030203160
776	0	8	_iPrinted edition: _z9783030203177
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-20315-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0 _zSI